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Abstract 
Purpose: In addition to the four histopathologically defined entities of medulloblastoma 
(MB), four distinct genetically defined subgroups have been included in the WHO 
classification of 2016. The smallest subgroup is the medulloblastoma with activated 
wingless pathway (WNT-MB). The goal of this study was to identify a typical MR-
morphology in a larger number of pediatric patients with WNT-MB. 
 
Methods: 38 WNT-MB cases were obtained from the database of the German 
pediatric brain tumor (HIT) - trials. Pediatric patients with histological subtyping and 
molecular confirmation of WNT-activation and adequate imaging data were included. 
Images were rated by standardized imaging criteria and a modified laterality score 
(LS).  
 
Results: 36/38 presented with classic histology. 28/38 (73.7%) were primary midline 
tumors but with a lateral tendency in 39.3%. One extensively eccentric midline tumor 
was rated by the LS as off-midline position. Five tumors were found in the 
cerebellopontine angle, three in the deep white matter and two in a cerebellar 
hemisphere. Leptomeningeal dissemination was rare. In 60.5% intratumoral blood 
degradation products were found and 26.3% showed cysts with blood contents. T2-
signal intensity was low. Contrast enhancement was moderate to strong predominantly 
in 76-100% of tumor volume.  
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Conclusion: This is the largest pediatric WNT-MB cohort systematically examined for 
MRI characteristics thus far. According to our observations WNT-MBs are not 
preferentially off-midline tumors as postulated in previous studies with smaller WNT-
MB cohorts. Dense intratumoral blood degradation products and cysts with blood 
contents are frequently found and might help to differentiate WNT-MB from other MB-
subtypes. 
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Introduction 
According to the revised WHO classification of tumors of the CNS of 20161 
medulloblastoma (MB) is not considered a single tumor entity but represents several 
entities with different cell of origin, location, biology, (epi)genetic alterations, histology 
and clinical behavior. According to the concept of an integrated diagnosis in the WHO 
classification of 2016, medulloblastoma entities are defined by both, histological and 
molecular/genetic features, allowing a precise assignment of patients for risk-adapted 
stratification in current therapeutic studies and the comparison to results of study 
cohorts in the past. All medulloblastoma entities correspond to WHO grade IV. For 
definition of the histological diagnosis, the tumors should be assigned to one of the 
four entities: classic (CMB), desmoplastic nodular (DNMB), extensive nodular (MBEN), 
or large cell/anaplastic (LC/A-MB) medulloblastoma. Large cell MB (LCMB) and 
anaplastic MB (AMB) were separated histologically entities before 2016.2 In addition 
to these histologically entities, four genetically defined subgroups have been 
introduced by the WHO classification of 20161. Two subgroups are defined by their 
genetic pathway, wingless activated (WNT) and sonic hedgehog activated (SHH) MB, 
the latter with or without accompanying TP53 mutation. The non-WNT/non-SHH 
subgroup is provisionally subclassified into group 3 and 4 medulloblastoma which 
seem to be overlapping variants. WNT-MB are characterized by activating mutations 
of CTNNB13,4, which encodes a central component of the WNT pathway or, 
alternatively, by inactivating mutations of APC3,5, AXIN16,7 or AXIN28 leading to nuclear 
accumulation of β-catenin. Accounting for approximately 10 %9,10 of all MB, WNT-MB 
form a small but distinct MB entity. In children, they show a significantly better 
progression-free survival and overall survival compared to other subgroups.4,9,10,11 In 
patients with WNT-MB younger than 16 years at diagnosis a progression-free survival 
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of 100% over 5 years has been observed.11 Current therapy studies, such as the SIOP-
PNET5 medulloblastoma trial, have implemented upfront genetic evaluation so that 
low-risk WNT-MB patients are eligible for radiotherapy reduction aimed at reducing late 
effects, with the therapy increasingly being adapted to the specific risk profile of each 
patient. Additionally, radiological imaging signatures have become apparent for certain 
brain tumors and their underlying genetic profile. The term “radiomics” is increasingly 
applied to describe the association between imaging phenotype and tumor genotype. 
Radiomics knowledge can become clinically meaningful, e.g. it offers surgeons a better 
preoperative procedure planning according to the presumed relapse risk of the tumor. 
Besides standard imaging characteristics, radiological studies have mainly focused on 
correlations of tumor position and genetic information. A first radiological subgroup 
analysis showed a preferential tumor location for WNT-MB in the cerebellopontine-
angle (CPA) and for SHH-MB in the cerebellar hemisphere.12 More recent studies 
yielded contradictory results with regards to tumor localization.13 However, in these 
previous studies, the maximum sample size of WNT-MB reached 16 patients14. The 
goal of the present study was to analyze structural MRI features according to defined 
MRI criteria in a uniquely large number of genetically determined WNT-MB (n=38) in 
children within the framework of the German pediatric brain tumor (HIT) - trials and the 
National Reference Center for Neuroradiology.  
 
  
5 
 
Material and Method 
Study Cohort 
Cases were retrospectively collected from the database of the National Reference 
Center for Neuroradiology (Department for Neuroradiology, Wuerzburg University 
Hospital) of the German brain tumor (HIT) - trials, conducted in German-speaking 
countries of Europe. All patients were registered to the HIT-2000 trial (NCT00303810) 
(including the German PNET 4-cohort [NCT01351870]), the HIT-2000 interim registry 
(NCT02238899), the I-HIT-MED registry (NCT02417324) or SIOP-PNET 5 MB trial 
(NCT02066220). Each patient or legal guardian signed an informed consent 
declaration allowing the scientific evaluation of biological and imaging data when 
entering the study. All cases were centrally reviewed at the National Brain Tumor 
Reference Center of the German Society of Neuropathology and Neuroanatomy 
(DGNN) (Institute of Neuropathology, Bonn University). Patients were eligible if they 
had a) histopathological and genetic classification data and b) preoperative cranial and 
spinal imaging data. Images on X-ray films and examinations with strong movement 
artefacts were excluded.  
 
Molecular Analysis 
Histological diagnosis was made at inclusion into the trial according to the WHO 
classification valid at the time of inclusion. Patients were diagnosed by a combination 
of histological examination by immunohistochemistry (IHC) and Sanger sequencing of 
exon 3 of CTNNB1.15,16 In case of negative CTNNB1-mutation, APC, AXIN1 and AXIN2 
sequence was assessed additionally.11 Neuropathological evaluation and CTNNB1 
mutational analysis were supplemented by 450k DNA methylation microarray 
(Illumina) if applicable.17,18 Where tissue was too scarce for analysis by methylation 
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microarray, subgroup was assigned using the mass spectrometry-minimal methylation 
classifier (MS-MIMIC) assay in addition to IHC and CTNNB1 mutational analysis.11,19 
Where initial workup did not include prospective assessment of WNT-activation, this 
was done during retrospective workup as previously described.11,17 Patients were 
considered to have WNT-MB if molecular analysis confirmed a mutation in CTNNB1 
or APC and/or assignment to the WNT-subgroup by methylation profiling or MS-
MIMIC. 
 
Imaging analysis 
All MRI datasets were assessed in consensus by two neuroradiologists dedicated to 
pediatric brain tumor imaging (M. W.-M. and A. S.).  
Multicenter data acquisition resulted in nonuniform MRI protocols, sequence 
technique, parameters and field strength. Local standardized diagnostic parameters 
were supplemented and used for the imaging assessment. The primary tumor location 
was determined as: cerebellar hemisphere, deep white matter, CPA, cerebellar vermis 
or fourth ventricle (figure 1). Deep white matter, cerebellar hemisphere and CPA were 
rated as primary lateral position. When the CPA was involved, the status of the fourth 
ventricle and the foramen of Magendie were recorded additionally. Fourth ventricle and 
cerebellar vermis were defined as primary midline positions. Additionally, laterality of 
primary midline tumors was assessed according to a modification of the laterality score 
(LS) by Patay et al14. Primary position in the fourth ventricle or the cerebellar vermis 
were rated as midline (LS-0). Fourth ventricle or cerebellar vermis plus bilateral recess 
extension were rated as LS-0 as well. Midline tumors were rated as moderately 
lateralized in case of tumor extension into only unilateral recess or bilateral recesses 
plus one CPA (LS-1). Extension into only the unilateral recess and further into the 
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ipsilateral CPA was rated as heavily lateralized and off-midline (L-2). The tumor volume 
is calculated using the (approximation of the ellipsoid volume) formula A x B x C ½ 
where A, B, and C are the maximum dimension in the standard anteroposterior, 
craniocaudal and transverse planes. The largest diameter of the perifocal edema was 
measured in centimeters. Signal intensity and homogeneity of the tumor were 
assessed in comparison to grey matter on T2WI and T1WI without contrast 
enhancement. Intensity and percentage of enhancing volume after gadolinium 
application were estimated. The contrast enhancing area of the tumor mass is mainly 
diffuse wherefore the rating was subjective in approximate percentages (0 - 25%, 26 - 
50%, 51 - 75%, 76 - 100%). Hydrocephalus was rated as slight, moderate and severe 
(slight meaning only visible dilatation of the ventricles, moderate showing CSF 
pressure caps and severe showing pressure caps with compression of the sulci at the 
vertex). Fluid of intratumoral cysts was compared to the signal of CSF and defined as: 
as bright as CSF, brighter than CSF, presence of blood degradation products like met-
hemoglobin or hemosiderin. Presence of blood degradation products like 
methemoglobin and hemosiderin in solid tumor mass was rated as: no blood 
degradation products, blood degradation products in less than 50 % of the tumor 
volume and blood degradation products in more than 50 % of the tumor mass. 
Leptomeningeal dissemination was assessed only by MRI according to the Chang 
classification.20 Cranial dissemination was rated as M2, spinal dissemination as M3 
and cranial plus spinal dissemination as M2+3. 
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Results 
In 38 of 75 patients with WNT-MB, adequate image datasets of preoperative cranial 
MRI and pre- or postoperative spinal MRI were available for analysis. In this MRI 
cohort, age ranged from 5 to 21.6 years (median 12.8 ± 4.6 years) and a female 
predominance (1.71:1; female:male-ratio) was found. According to traditional 
histopathological criteria, most WNT-MB cases of this cohort were CMB (36/38; 
94.7%), further 2 LC/A-MB (one AMB and one LCMB [2.6% each], diagnosed before 
2016). Thirty-four tumors were diagnosed by a combination of immunohistochemistry 
(IHC) and Sanger sequencing of exon 3 of CTNNB1, each with a detectable mutation 
of CTNNB1. In fifteen of these patients, 450k methylation microarray was 
supplemented and classified all tumors as WNT. There were two cases without Sanger 
sequencing; one was categorized as WNT-activated by MS-MIMIC assay and the other 
one by 450k methylation microarray. In one tumor, CTNNB1 mutational analysis was 
negative but was classified as WNT subgroup by 450k methylation microarray analysis 
and additionally a copy-neutral loss of heterozygosity within chromosome arm 5q 
(APC) and a R213* mutation in the APC gene were identified. One patient was 
diagnosed as WNT-MB based on tissue of tumor recurrence; here, CTNNB1 mutation 
and WNT-activation in 450k methylation microarray were detectable.  
An overview of the MRI features is shown in table 1 and primary tumor localization and 
extension are presented in table 2. Twenty-eight tumors were primarily located in the 
midline position. Fourteen of 25 (56%) WNT-MB in the fourth ventricle and 2 of 3 in the 
cerebellar vermis were midline tumors without lateral tendency (LS-0). Eleven of 28 
(39.3%) WNT-MB showed extension into one recess only or into both recesses with 
further extension into only one CPA (LS-1). Only one WNT-MB located in the fourth 
ventricle, extended into a unilateral recess and further the ipsilateral CPA (LS-2). In 
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summary, 74% of all WNT-MB showed primarily a midline position but only 42% 
represented “pure” midline tumors, with nearly half of the midline tumors showing a 
lateral tendency (39.3%). Only one (3.6%) primarily midline-located WNT-MB was 
rated as off-midline according to our LS score because of its strong eccentric position. 
Five of 38 (13%) WNT-MB were positioned in the cerebellopontine angle, 2 of 38 (5%) 
in the cerebellar hemisphere and 3 of 38 (8%) in the deep white matter. These positions 
were rated as off-midline. One CPA tumor showed some extension into the fourth 
ventricle. In both cerebellar hemispheric tumors, the ipsilateral recess was involved. 
One tumor with its epicenter in the deep white matter expanded into the fourth ventricle 
and one into the ipsilateral recess. 
Most WNT-MB were moderately (39.5%) to very sharply (42.1%) delineated. Eighteen 
of 38 (47.4%) WNT-MB contained cysts. In ten of 18 (55.6%) partly cystic tumors, the 
cysts contained blood degradation products, visible as blood-fluid levels (figure 2). The 
cyst contents were brighter than cerebrospinal fluid in 27.8% and similar to 
cerebrospinal fluid in 16.7%. Twenty-three patients had a hydrocephalus. Six (15.8%) 
patients showed a slight and 15 (39.5 %) patients a moderate hydrocephalus, only two 
patients (5.3 %) had a severe hydrocephalus. Fifteen (39.5%) patients had no 
hydrocephalus at diagnosis. Tumor signal-intensity in T2WI compared to the 
supratentorial cortex was predominantly isointense (54.1%) to hypointense (35.1%). 
Only four tumors (10.8%) were hyperintense in comparison to the signal intensity of 
the cortex on T2WI. In one child, no standard T2-sequence but a FLAIR-sequence was 
available for evaluation. Thirty-one (83.8%) tumors showed inhomogeneous signal on 
T2WI, only 6 of 37 (16.2%) showed homogeneous signal. On T1WI the signal-intensity 
was hypointense in 27 of 38 (75%). Eight (22.2%) tumors showed an isointense signal 
and only one tumor (2.8%) showed a completely hyperintense signal. Two patients had 
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no standard unenhanced T1WI at diagnosis. Signal on T1WI was homogeneous in 
41.7 % and inhomogeneous in 58.3%. Thirty-six of 38 (94.7%) WNT-MB showed 
contrast enhancement in 76 - 100% of the tumor volume, only 1 WNT-MB showed an 
enhancing volume of 26 - 50% and 1 WNT-MB 0 - 25%. Signs of bleeding in T1WI, 
T2WI or susceptibility-weighted images were found in 23/38 (60.5%). In 18 of those 
cases, susceptibility- weighted images as SWI or T2*-sequences had been acquired. 
Sixteen of 18 (88.9%) susceptibility- weighted images showed iron contents. Five of 
18 MB showed iron deposition in more than 50 % of the tumor mass. The extension of 
perifocal edema ranged from 0 to 2.6 cm (mean 0.66 ± 0.62 cm). Twenty-seven of 38 
(71.1%) MBs showed perifocal edema. Tumor volume ranged from 2.68 cm³ to 68.59 
cm³ (mean 27.79 ± 16.87 cm³). LCMB are usually significantly smaller than other 
histological MB-types (mean 15 cm³) as described previously.21 Using this value from 
the literature as cut-off between large and small tumor size 10 of 40 WNT-tumors were 
very small (range 2.68 - 12.77 cm³), all of them presented classic histology. The two 
LC/A MBs had volumes of 29.81 cm³ and 46.39 cm³. Leptomeningeal dissemination at 
diagnosis was assessable in 35 patients and positive in 11.5% (4 of 35). One patient 
showed cranial dissemination (M2), two had cranial and spinal dissemination (M2+3) 
and one patient showed isolated spinal dissemination (M3). All four disseminated 
WNT-MB showed classic histology in the primary tumor. 
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Table 1: Overview of absolute and relative (%) frequency of MRI features. 
    
available 
data n % 
Sex  38   
 male  14 36.8 
 female  24 63.2 
Histology  38   
 CMB  36 94.7 
 AMB*  1 2.6 
 LCMB*  1 2.6 
Hydrocephalus  38   
 no  15 39.5 
 slight  6 15.8 
 moderate  15 39.5 
 severe  2 5.3 
Enhancement  38   
 no  0 0 
 light  4 10.5 
 moderate  12 31.6 
 strong  22 57.9 
Enhancing area  38   
 0 - 25 %  0 0 
 26 % - 50 %  1 2.6 
 51 % - 75 %  1 2.6 
 76 % - 100 %  36 94.7 
T2-weighted images  37   
 homogeneus   6 16.2 
 inhomogeneus   31 83.8 
 hyperintense  4 10.8 
 isointense  20 54.1 
 hypointense  13 35.1 
T1-weighted images  36   
 homogeneus  15 41.7 
 inhomogeneus   21 58.3 
 hyperintense  1 2.8 
 isointense  8 22.2 
 hypointense  27 75 
Cysts  38   
 no  20 52.6 
 
as bright as the 
CSF  3 7.9 
 brighter than the CSF 5 13.2 
 blood-fluid level  10 26.3 
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Blood degradation 
products on T1w, 
T2w or T2*/SWI  38   
 yes  23 60.5 
 no  15 39.5 
Mass of iron 
contents on T2*/SWI  18   
 no  2 11.1 
 < 50 %  11 61.1 
 > 50 %  5 27.8 
Dissemination  35   
 no  31 88.6 
 M2  1 2.9 
 M3  1 2.9 
  M2+3   2 5.7 
* according to the WHO classification of 2007    
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Table 2: Overview of the tumor proposed epicenter and direction of extension. 
primary 
location 
number of WNT-
MB (n) extension   
further 
extension   LS 
fourth ventricle n = 25 (66 %) 
unilateral 
recess n = 7 plus uni CPA n = 1 2 
      no n = 6 1 
  
bilateral 
recesses n = 16 plus uni CPA n = 4 1 
    plus bi CPA n = 0 0 
    no n = 12 0 
    no extension n = 2     0 
cerebellar 
vermis n = 3 (8 %) 
unilateral 
recess n = 1     1 
  
bilateral 
recesses n = 1     0 
  
fourth ventricle 
only n = 1     0 
    no extension n = 0     0 
CPA n = 5 (13 %) 
unilateral 
recess n = 4 
plus fourth 
ventricle n = 4 2 
  
bilateral 
recesses n = 0   2 
    no extension n = 1     2 
deep white 
matter n = 3 (8 %) 
unilateral 
recess n = 1 plus uni CPA n = 1 2 
  
bilateral 
recesses n = 0   2 
  
fourth ventricle 
only n = 1   2 
    no extension n = 1      
cerebellar 
hemisphere n = 2 (5 %) 
unilateral 
recess n = 2 plus uni CPA n = 1 2 
  
bilateral 
recesses n = 0   2 
  
fourth ventricle 
only n = 0   2 
    no extension n = 0     2 
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Discussion 
To our knowledge, this series represents the largest cohort of WNT-MBs analyzed for 
characteristic MRI features thus far. Our results show that the preferred primary 
position of our WNT-MBs is the midline fourth ventricle or vermis 28 of 38 (74%). 
Perreault et al.12 were the first to report that WNT-MB are characterized by an off-
midline position in 75% (3 of 4 were located in the CPA or cerebellar peduncle) leading 
to a positive predictive value of 100% for this tumor site. In our cohort only 5 of 38 
(13%) WNT-MB had their epicenter in the CPA, altogether only 26% were primarily 
located in an off-midline position. This is much lower compared to earlier study 
results.12,13,14 Gibson et al.22 indicated that WNT-MB arise in the lower rhombic limb 
from progenitor cells of nuclei in the dorsal brainstem. However, all six WNT-MB in this 
publication were reported as midline tumors and were opposed to the SHH-activated 
MBs. Similarly, Łastowska et al.23 found 5/6 and Teo et al.24 described five WNT-MB 
in midline position. Based on Gibson`s hypothesis on the individual tumor origin the 
pathways of extension were evaluated in more detail. With a self-defined score, Patay 
et al.14 emphasized the lateralized position of WNT-MB (50% off-midline position). We 
support Patay's conclusion that WNT-MB are paramedian midline tumors describing a 
lateralized position in 22/38 tumors in our cohort. However, a purely CPA localization 
(5 of 38) seems to be much rarer than previously noted.12 The primary midline position 
is in line with the hypothesis that WNT-MB arise from the dorsal brainstem and grow 
within the CSF spaces. Notably the fourth ventricle may be the preferred pathway of 
tumor growth, as it offers the least resistance. With only three tumors having their 
epicenter in the deep white matter surrounding the fourth ventricle in our study, this 
localization was significantly less frequent compared to previous studies (8% versus 
20%).13 While Perreault et al.12 and Mata-Mbemba et al.13 assigned a cerebellar 
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hemispheric origin as highly predictive of SHH-activated MB, we found 2 WNT-tumors 
located in the cerebellar hemisphere. However, both tumors were large, rendering the 
definition of their origin in differentiation between hemisphere and paraventricular white 
matter to be challenging. These different tumor locations in our cohort and partially 
divergent results compared to the previous studies questions whether off-midline or 
midline position is of any useful diagnostic predictive value. The four genetic subgroup 
model was refined by Taylor et al.25 in 2012 and has been updated recently.26,27,28 
Further refined definitions of substructures within the four WHO entities of MB may be 
expected. The existence of such substructures might be a possible cause for the 
heterogeneity of the tumor’s epicenter in our study and the divergent reports of the 
typical location of WNT-MB in previous studies. 
The children in our cohort were older than four years, this matches previous 
observations that WNT-MB do not typically occur in early childhood.9 Most WNT-MB 
in our cohort were histologically CMB, but there were single other histological types 
(LC/A-MB, n = 2) as well. The fact that WNT-MBs are not exclusively CMB has been 
reported previously.9,10,13 Our cohort contained one tumor corresponding to LCMB 
(according to the WHO classification of 2007). This is in accordance with Ellison et al.9 
and Kool et al.10 reporting 2% LCMB among their group of WNT-MB.9,10 With a mean 
tumor volume of 15 cm³ LCMBs have been described as significantly smaller than other 
histological types of MB.21 Interestingly, 10 CMBs in our cohort had a tumor size of 
less than 15 cm³ and the only LCMB showed double that size. Leptomeningeal 
dissemination of WNT-MBs had not yet been reported in other neuroradiological 
studies.13,29 In our cohort 11.5% patients showed a macroscopic leptomeningeal 
dissemination at diagnosis. This percentage is similar to the numbers reported in 
studies on neuropathology.9 We found a female predominance which is contrary to the 
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cohort of Patay et al.14. The female predominance in our cohort should be considered 
with caution due to the small cohort size in comparison to publications that have 
recorded the demographic data of significantly more WNT-MB and found no 
predominance for male or female.9,10,25 MB are tumors of high cellularity for which a 
lower signal on T2WI can be expected. In our cohort, WNT-MBs were primarily iso- to 
hypointense in T2WI. The comparatively low T2-signal is useful to differentiate MBs 
from pilocytic astrocytomas and, to a lesser extent, also from ependymomas. 
Inhomogeneous signal on T2WI and the moderate to strong contrast enhancement do 
not seem to be specific criteria to separate WNT-MBs from other highly cellular tumors 
e.g. atypical teratoid rhabdoid tumors. Blood residues are not common in MBs. Patay 
et al.14 reported blood degradation products in 31.25% of assessed tumors, while 
Perreault et al.12 did not find subgroup specific features on iron sensitive images. 
However, the high number of tumors showing large areas of met-hemoglobin or 
hemosiderin and cysts containing blood degradation products with blood-fluid levels 
was remarkable in our evaluation.  
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Conclusion 
WNT-MB are found predominately in the fourth ventricle. However, a certain laterality 
can be noted by their hypothetical point of origin and possible growth characteristics. 
However, hemispherically positioned WNT-MB and leptomeningeal dissemination can 
occur and may not be used as a criterion to exclude WNT-MB. Dense intratumoral 
blood degradation products and cysts with blood contents are frequently found and 
might help to differentiate WNT-MB from other MB-subtypes. 
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Figure legends 
Figure 1: Examples for primary tumor position in WNT-MB: A) midline fourth ventricle, 
B) cerebellopontine angle, C) cerebellar hemisphere, D) midline cerebellar vermis, E) 
periventricular deep white matter. 
 
Figure 2: A) Deoxygenated blood in T2*-WI. B) Intratumoral cyst with a blood-fluid level 
(→). C) Inhomogeneous signal in T2-WI. D) Hypointense signal in T1-WI and small 
areas of methemoglobin (e.g. →). D) 100% contrast enhancement. E) Leptomeningeal 
dissemination, M2 on the floor of the third ventricle (→). 
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Abbreviations 
 
AMB  anaplastic medulloblastoma (according to the WHO classification 
of 2007) 
CMB   classic medulloblastoma 
CPA   cerebellopontine angle 
DNMB  desmoplastic / nodular medulloblastoma 
IHC   immunohistochemistry 
LCMB  large cell medulloblastoma (according to the WHO classification 
of 2007) 
LC/A-MB  large cell / anaplastic medulloblastoma 
LS   laterality score 
MB   medulloblastoma 
MBEN  medulloblastoma with extensive nodularity 
MS-MIMIC  mass spectrometry-minimal methylation classifier  
SHH-MB  sonic hedgehog activated medulloblastoma 
WNT-MB  WNT activated medulloblastoma 
 
 
